daptomycin

Summary

Summary: A cyclic lipopeptide antibiotic that inhibits GRAM-POSITIVE BACTERIA.

Top Publications

  1. Rose W, Schulz L, Andes D, Striker R, Berti A, Hutson P, et al. Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity. Antimicrob Agents Chemother. 2012;56:5296-302 pubmed publisher
    Antistaphylococcal beta-lactams enhance daptomycin activity and have been used successfully in combination for refractory methicillin-resistant Staphylococcus aureus (MRSA) infections...
  2. Durante Mangoni E, Casillo R, Bernardo M, Caianiello C, Mattucci I, Pinto D, et al. High-dose daptomycin for cardiac implantable electronic device-related infective endocarditis. Clin Infect Dis. 2012;54:347-54 pubmed publisher
    ..b>Daptomycin at the dose of 6 mg/kg/day has been found to be effective in staphylococcal endocarditis, but limited data exist ..
  3. Yu G, Jia X, Wen J, Lu W, Wang G, Caiyin Q, et al. Strain improvement of Streptomyces roseosporus for daptomycin production by rational screening of He-Ne laser and NTG induced mutants and kinetic modeling. Appl Biochem Biotechnol. 2011;163:729-43 pubmed publisher
    To improve the yield of daptomycin by Streptomyces roseosporus, a method of rational screening of He-Ne Laser and N-methyl-N-nitro-N-nitrosoguanidine (NTG)-induced mutants was employed in this work...
  4. John A, Schmaler M, Khanna N, Landmann R. Reversible daptomycin tolerance of adherent staphylococci in an implant infection model. Antimicrob Agents Chemother. 2011;55:3510-6 pubmed publisher
    b>Daptomycin (DAP) is bactericidal against methicillin-resistant Staphylococcus aureus (MRSA) in vitro, but it failed to eradicate MRSA in an experimental model of implant-associated infection...
  5. D Souza N, Shetty A, Mehta A, Rodrigues C. Antimicrobial susceptibility profiles of meticillin-susceptible and -resistant Staphylococcus aureus: focus on daptomycin minimum inhibitory concentrations at a tertiary care centre in Mumbai, India. Int J Antimicrob Agents. 2010;36:267-70 pubmed publisher
    In this study, daptomycin minimum inhibitory concentrations (MICs) for Staphylococcus aureus isolates were determined using Etest strips and were correlated with staphylococcal cassette chromosome mec (SCCmec) types and Panton-Valentine ..
  6. Konychev A, Heep M, Moritz R, Kreuter A, Shulutko A, Fierlbeck G, et al. Safety and efficacy of daptomycin as first-line treatment for complicated skin and soft tissue infections in elderly patients: an open-label, multicentre, randomized phase IIIb trial. Drugs Aging. 2013;30:829-36 pubmed publisher
    b>Daptomycin has proven efficacy in patients with Gram-positive complicated skin and soft tissue infections (cSSTIs), including those caused by Staphylococcus aureus, regardless of methicillin susceptibility.
  7. Rubio A, Moore J, Varoglu M, Conrad M, Chu M, Shaw W, et al. LC-MS/MS characterization of phospholipid content in daptomycin-susceptible and -resistant isolates of Staphylococcus aureus with mutations in mprF. Mol Membr Biol. 2012;29:1-8 pubmed publisher
    b>Daptomycin (DAP) is a cyclic lipopeptide antibiotic used for the treatment of certain Staphylococcus aureus infections. Although rare, strains have been isolated that are DAP resistant...
  8. Jacqueline C, Amador G, Batard E, Le Mabecque V, Miegeville A, Biek D, et al. Comparison of ceftaroline fosamil, daptomycin and tigecycline in an experimental rabbit endocarditis model caused by methicillin-susceptible, methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus. J Antimicrob Chemother. 2011;66:863-6 pubmed publisher
    ..aim of this study was to compare the in vivo activities of the new antistaphylococcal drugs ceftaroline fosamil, daptomycin and tigecycline at projected human therapeutic doses against methicillin-susceptible Staphylococcus aureus (MSSA)..
  9. Moise P, Amodio Groton M, Rashid M, Lamp K, Hoffman Roberts H, Sakoulas G, et al. Multicenter evaluation of the clinical outcomes of daptomycin with and without concomitant ?-lactams in patients with Staphylococcus aureus bacteremia and mild to moderate renal impairment. Antimicrob Agents Chemother. 2013;57:1192-200 pubmed publisher
    ..In light of recent data demonstrating the successful use of ?-lactam plus daptomycin in very difficult cases of S...

More Information

Publications62

  1. Bayer A, Schneider T, Sahl H. Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall. Ann N Y Acad Sci. 2013;1277:139-58 pubmed publisher
    The bactericidal, cell membrane-targeting lipopeptide antibiotic daptomycin (DAP) is an important agent in treating invasive Staphylococcus aureus infections...
  2. Olson M, Slater S, Rupp M, Fey P. Rifampicin enhances activity of daptomycin and vancomycin against both a polysaccharide intercellular adhesin (PIA)-dependent and -independent Staphylococcus epidermidis biofilm. J Antimicrob Chemother. 2010;65:2164-71 pubmed publisher
    This study addressed the efficacy of daptomycin, vancomycin, rifampicin, daptomycin/rifampicin and vancomycin/rifampicin against a polysaccharide intercellular adhesin (PIA)-dependent and -independent Staphylococcus epidermidis biofilm ..
  3. Liao G, Shi T, Xie J. Regulation mechanisms underlying the biosynthesis of daptomycin and related lipopeptides. J Cell Biochem. 2012;113:735-41 pubmed publisher
    b>Daptomycin is a lipopeptide antibiotics used to treat Gram-positive pathogens infections, including drug-resistant strains...
  4. Falcone M, Russo A, Venditti M, Novelli A, Pai M. Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2013;57:1568-76 pubmed publisher
    Higher daptomycin doses are advocated for select methicillin-resistant Staphylococcus aureus (MRSA)-related infections, but the probabilities of target attainment (PTA) and toxicity of these doses have not been characterized in critically ..
  5. Eckmann C, Dryden M. Treatment of complicated skin and soft-tissue infections caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and vancomycin. Eur J Med Res. 2010;15:554-63 pubmed
    ..Linezolid, tigecycline, daptomycin and vancomycin showed efficacy and safety in MRSA-caused cSSTI...
  6. Keel R, Sutherland C, Aslanzadeh J, Nicolau D, Kuti J. Correlation between vancomycin and daptomycin MIC values for methicillin-susceptible and methicillin-resistant Staphylococcus aureus by 3 testing methodologies. Diagn Microbiol Infect Dis. 2010;68:326-9 pubmed publisher
    We examined the potential correlation between vancomycin and daptomycin MIC for 298 Staphylococcus aureus by broth microdilution (BMD), Etest, and MicroScan(®)...
  7. Kelesidis T, Chow A, Humphries R, Uslan D, Pegues D. Case-control study comparing de novo and daptomycin-exposed daptomycin-nonsusceptible Enterococcus infections. Antimicrob Agents Chemother. 2012;56:2150-2 pubmed publisher
    Understanding factors associated with de novo daptomycin-nonsusceptible Enterococcus (DNSE) infections will aid in better understanding the mechanisms of daptomycin nonsusceptibility...
  8. Dhand A, Bayer A, POGLIANO J, Yang S, Bolaris M, Nizet V, et al. Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin Infect Dis. 2011;53:158-63 pubmed publisher
    We used daptomycin plus antistaphylococcal ?-lactams (ASBL) to clear refractory MRSA bacteremia...
  9. Ambrosch A, Halevy D, Fwity B, Brin T, Lobmann R. Effect of daptomycin on local interleukin-6, matrix metalloproteinase-9, and metallopeptidase inhibitor 1 in patients with MRSA-infected diabetic foot. Int J Low Extrem Wounds. 2013;12:100-5 pubmed publisher
    ..grades 2 or 3 (corresponding to the Texas classification stage 2 and 3) during antibiotic treatment with daptomycin. We documented the wound size and obtained samples of wound secretion for analyses of pro-inflammatory ..
  10. Murray K, Zhao J, Davis S, Kullar R, Kaye K, Lephart P, et al. Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1 mg/L: a matched cohort study. Clin Infect Dis. 2013;56:1562-9 pubmed publisher
    ..This matched, retrospective cohort study compared the clinical effectiveness of daptomycin with that of vancomycin for the treatment of MRSAB with vancomycin MICs >1 µg/mL...
  11. Rubio A, Conrad M, Haselbeck R, G C K, Brown Driver V, Finn J, et al. Regulation of mprF by antisense RNA restores daptomycin susceptibility to daptomycin-resistant isolates of Staphylococcus aureus. Antimicrob Agents Chemother. 2011;55:364-7 pubmed publisher
    Mutations in mprF have been shown to result in reduced susceptibility to daptomycin and other cationic antibacterials...
  12. Humphries R, Pollett S, Sakoulas G. A current perspective on daptomycin for the clinical microbiologist. Clin Microbiol Rev. 2013;26:759-80 pubmed publisher
    b>Daptomycin is a lipopeptide antimicrobial with in vitro bactericidal activity against Gram-positive bacteria that was first approved for clinical use in 2004 in the United States...
  13. Pogliano J, Pogliano N, Silverman J. Daptomycin-mediated reorganization of membrane architecture causes mislocalization of essential cell division proteins. J Bacteriol. 2012;194:4494-504 pubmed publisher
    b>Daptomycin is a lipopeptide antibiotic used clinically for the treatment of certain types of Gram-positive infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA)...
  14. Sader H, Moet G, Farrell D, Jones R. Antimicrobial susceptibility of daptomycin and comparator agents tested against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: trend analysis of a 6-year period in US medical centers (2005-2010). Diagn Microbiol Infect Dis. 2011;70:412-6 pubmed publisher
    We evaluated daptomycin activity trends against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE; MIC, ?8 ?g/mL) in a 6-year period (2005-2010) following US regulatory release for clinical use...
  15. Grandgirard D, Burri M, Agyeman P, Leib S. Adjunctive daptomycin attenuates brain damage and hearing loss more efficiently than rifampin in infant rat pneumococcal meningitis. Antimicrob Agents Chemother. 2012;56:4289-95 pubmed publisher
    ..b>Daptomycin, a nonlytic antibiotic acting on Gram-positive bacteria, lessens inflammation and brain injury compared to ..
  16. Bazoti F, Gikas E, Skoutelis A, Tsarbopoulos A. Development and validation of an ultra performance liquid chromatography-tandem mass spectrometry method for the quantification of daptomycin in human plasma. J Pharm Biomed Anal. 2011;56:78-85 pubmed publisher
    ..MS/MS) on a hybrid q TOF instrument has been developed and fully validated for the quantification of daptomycin (DPT) in human plasma...
  17. Wang L, Zhao Y, Liu Q, Huang Y, Hu C, Liao G. Improvement of A21978C production in Streptomyces roseosporus by reporter-guided rpsL mutation selection. J Appl Microbiol. 2012;112:1095-101 pubmed publisher
    b>Daptomycin, one of the A21978C factors produced by Streptomyces roseosporus, is an acidic cyclic lipopeptide antibiotic with potent activity against a variety of Gram-positive pathogens...
  18. Fajardo Olivares M, Hidalgo Orozco R, Rodríguez Garrido S, Rodríguez Vidigal F, Vera Tomé A, Robles Marcos M. Activity of vancomycin, ciprofloxacin, daptomycin, and linezolid against coagulase-negative staphylococci bacteremia. Rev Esp Quimioter. 2011;24:74-8 pubmed
    ..We have studied the activity of vancomycin, ciprofloxacin, daptomycin and linezolid in methicillin-resistant CNS strains, isolated from true blood cultures.
  19. Campbell M, Marchaim D, Pogue J, Sunkara B, Bheemreddy S, Bathina P, et al. Treatment of methicillin-resistant Staphylococcus aureus infections with a minimal inhibitory concentration of 2 ?g/mL to vancomycin: old (trimethoprim/sulfamethoxazole) versus new (daptomycin or linezolid) agents. Ann Pharmacother. 2012;46:1587-97 pubmed publisher
    ..Alternative therapeutic options include daptomycin and linezolid, 2 relatively new and expensive drugs, and trimethoprim/sulfamethoxazole (TMP/SMX), an old and ..
  20. Larioza J, Girard A, Brown R. Clinical experience with daptomycin for outpatient parenteral antibiotic therapy. Am J Med Sci. 2011;342:486-8 pubmed publisher
    ..reviewed the experience of a single institution using outpatient parenteral antibiotic therapy with daptomycin as monotherapy...
  21. Kamboj M, Cohen N, Gilhuley K, Babady N, Seo S, Sepkowitz K. Emergence of daptomycin-resistant VRE: experience of a single institution. Infect Control Hosp Epidemiol. 2011;32:391-4 pubmed publisher
    ..5% of vancomycin-resistant enterococci (VRE) isolates remain susceptible to daptomycin. This report describes emergence of daptomycin-resistant VRE at a major cancer center...
  22. Muraih J, Pearson A, Silverman J, Palmer M. Oligomerization of daptomycin on membranes. Biochim Biophys Acta. 2011;1808:1154-60 pubmed publisher
    b>Daptomycin is a lipopeptide antibiotic that kills Gram-positive bacteria by membrane depolarization...
  23. Mishra N, Bayer A, Tran T, Shamoo Y, Mileykovskaya E, Dowhan W, et al. Daptomycin resistance in enterococci is associated with distinct alterations of cell membrane phospholipid content. PLoS ONE. 2012;7:e43958 pubmed publisher
    The lipopeptide antibiotic, daptomycin (DAP) interacts with the bacterial cell membrane (CM)...
  24. Yang S, Mishra N, Rubio A, Bayer A. Causal role of single nucleotide polymorphisms within the mprF gene of Staphylococcus aureus in daptomycin resistance. Antimicrob Agents Chemother. 2013;57:5658-64 pubmed publisher
    Single nucleotide polymorphisms (SNPs) within the mprF open reading frame (ORF) have been commonly observed in daptomycin-resistant (DAP(r)) Staphylococcus aureus strains...
  25. Seaton R, Malizos K, Viale P, Gargalianos Kakolyris P, Santantonio T, Petrelli E, et al. Daptomycin use in patients with osteomyelitis: a preliminary report from the EU-CORE(SM) database. J Antimicrob Chemother. 2013;68:1642-9 pubmed publisher
    ..Because treatment failure or intolerance is common, new treatment options are needed. Daptomycin has broad Gram-positive activity, penetrates bone effectively and has bactericidal activity within biofilms...
  26. Arias C, Panesso D, McGrath D, Qin X, Mojica M, Miller C, et al. Genetic basis for in vivo daptomycin resistance in enterococci. N Engl J Med. 2011;365:892-900 pubmed publisher
    b>Daptomycin is a lipopeptide with bactericidal activity that acts on the cell membrane of enterococci and is often used off-label to treat patients infected with vancomycin-resistant enterococci...
  27. Kelesidis T, Humphries R, Uslan D, Pegues D. De novo daptomycin-nonsusceptible enterococcal infections. Emerg Infect Dis. 2012;18:674-6 pubmed publisher
    Potential emergence of enterococcal daptomycin nonsusceptibility among patients with no prior exposure to daptomycin poses clinical and public health challenges...
  28. Cui L, Isii T, Fukuda M, Ochiai T, Neoh H, Camargo I, et al. An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus. Antimicrob Agents Chemother. 2010;54:5222-33 pubmed publisher
    ..the establishment of a Staphylococcus aureus laboratory strain, 10 3d1, having reduced susceptibility to daptomycin and heterogeneous vancomycin-intermediate S. aureus (VISA) phenotype...
  29. Peleg A, Miyakis S, Ward D, Earl A, Rubio A, Cameron D, et al. Whole genome characterization of the mechanisms of daptomycin resistance in clinical and laboratory derived isolates of Staphylococcus aureus. PLoS ONE. 2012;7:e28316 pubmed publisher
    b>Daptomycin remains one of our last-line anti-staphylococcal agents. This study aims to characterize the genetic evolution to daptomycin resistance in S. aureus...
  30. Crompton J, North D, Yoon M, Steenbergen J, Lamp K, Forrest G. Outcomes with daptomycin in the treatment of Staphylococcus aureus infections with a range of vancomycin MICs. J Antimicrob Chemother. 2010;65:1784-91 pubmed publisher
    ..This study examines the outcome of patients treated with daptomycin for S. aureus infections with documented vancomycin MICs...
  31. Lefebvre M, Jacqueline C, Amador G, Le Mabecque V, Miegeville A, Potel G, et al. Efficacy of daptomycin combined with rifampicin for the treatment of experimental meticillin-resistant Staphylococcus aureus (MRSA) acute osteomyelitis. Int J Antimicrob Agents. 2010;36:542-4 pubmed publisher
    b>Daptomycin exhibits rapid bactericidal activity against Gram-positive organisms, including meticillin-resistant Staphylococcus aureus (MRSA). Daptomycin in combination with rifampicin needs to be assessed in bone infection...
  32. Marconescu P, Graviss E, Musher D. Rates of killing of methicillin-resistant Staphylococcus aureus by ceftaroline, daptomycin, and telavancin compared to that of vancomycin. Scand J Infect Dis. 2012;44:620-2 pubmed publisher
    ..time-kill assays to determine the in vitro killing rate of 22 strains of MRSA by vancomycin, telavancin, daptomycin, and ceftaroline...
  33. Mishra N, Bayer A, Moise P, Yeaman M, Sakoulas G. Reduced susceptibility to host-defense cationic peptides and daptomycin coemerge in methicillin-resistant Staphylococcus aureus from daptomycin-naive bacteremic patients. J Infect Dis. 2012;206:1160-7 pubmed
    We hypothesized that, for methicillin-resistant Staphylococcus aureus (MRSA), in vitro daptomycin susceptibility could be influenced by exposures to endogenous host defense peptides (HDPs) prior to clinical exposure to daptomycin...
  34. Hachmann A, Sevim E, Gaballa A, Popham D, Antelmann H, Helmann J. Reduction in membrane phosphatidylglycerol content leads to daptomycin resistance in Bacillus subtilis. Antimicrob Agents Chemother. 2011;55:4326-37 pubmed publisher
    b>Daptomycin (DAP) is a cyclic lipopeptide that disrupts the functional integrity of the cell membranes of Gram-positive bacteria in a Ca(2+)-dependent manner...
  35. Steed M, Vidaillac C, Rybak M. Evaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillin-resistant Staphylococcus aureus strains in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother. 2011;55:3522-6 pubmed publisher
    ..potential role of ceftaroline, a new broad-spectrum cephalosporin, as a therapeutic option for the treatment of daptomycin-nonsusceptible (DNS) methicillin-resistant Staphylococcus aureus (MRSA) infections...
  36. Crank C, Scheetz M, Brielmaier B, Rose W, Patel G, Ritchie D, et al. Comparison of outcomes from daptomycin or linezolid treatment for vancomycin-resistant enterococcal bloodstream infection: A retrospective, multicenter, cohort study. Clin Ther. 2010;32:1713-9 pubmed publisher
    ..This study examined outcomes in patients treated with daptomycin or linezolid for VRE BSI. A retrospective, multicenter, cohort study was performed via chart review...
  37. Cohen Wolkowiez M, Watt K, Hornik C, Benjamin D, Smith P. Pharmacokinetics and tolerability of single-dose daptomycin in young infants. Pediatr Infect Dis J. 2012;31:935-7 pubmed publisher
    b>Daptomycin is approved for the treatment of complicated skin and skin-structure infections and Staphylococcus aureus bacteremia. We sought to characterize daptomycin single-dose pharmacokinetics and tolerability in young infants...
  38. Hall A, Steed M, Arias C, Murray B, Rybak M. Evaluation of standard- and high-dose daptomycin versus linezolid against vancomycin-resistant Enterococcus isolates in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother. 2012;56:3174-80 pubmed publisher
    b>Daptomycin MICs for enterococci are typically 1- to 2-fold higher than those for Staphylococcus aureus, and there is an imminent need to establish the optimal dose for appropriate treatment of enterococcal infections...
  39. Kullar R, Chin J, Edwards D, Parker D, Coplin W, Rybak M. Pharmacokinetics of single-dose daptomycin in patients with suspected or confirmed neurological infections. Antimicrob Agents Chemother. 2011;55:3505-9 pubmed publisher
    There are currently few or no published data on the amount of cerebrospinal fluid (CSF) penetration of daptomycin in patients with suspected or documented neurosurgical infections...
  40. Aikawa N, Kusachi S, Mikamo H, Takesue Y, Watanabe S, Tanaka Y, et al. Efficacy and safety of intravenous daptomycin in Japanese patients with skin and soft tissue infections. J Infect Chemother. 2013;19:447-55 pubmed publisher
    b>Daptomycin is a lipopeptide antibiotic active against gram-positive organisms and recently approved for marketing in Japan...
  41. Humphries R, Kelesidis T, Tewhey R, Rose W, Schork N, Nizet V, et al. Genotypic and phenotypic evaluation of the evolution of high-level daptomycin nonsusceptibility in vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother. 2012;56:6051-3 pubmed publisher
    Whole-genome sequencing and cell membrane studies of three clonal Enterococcus faecium strains with daptomycin MICs of 4, 32, and 192 ?g/ml were performed, revealing nonsynonymous single nucleotide variants in eight open reading frames, ..
  42. Byren I, Rege S, Campanaro E, Yankelev S, Anastasiou D, Kuropatkin G, et al. Randomized controlled trial of the safety and efficacy of Daptomycin versus standard-of-care therapy for management of patients with osteomyelitis associated with prosthetic devices undergoing two-stage revision arthroplasty. Antimicrob Agents Chemother. 2012;56:5626-32 pubmed publisher
    ..of Staphylococcus aureus causing prosthetic joint infection (PJI) supports investigation of higher doses of daptomycin in the management of PJI...
  43. Cirioni O, Mocchegiani F, Cacciatore I, Vecchiet J, Silvestri C, Baldassarre L, et al. Quorum sensing inhibitor FS3-coated vascular graft enhances daptomycin efficacy in a rat model of staphylococcal infection. Peptides. 2013;40:77-81 pubmed publisher
    The aim of the study was to investigate the efficacy of the quorum sensing inhibitor FS3 and daptomycin in preventing prosthesis biofilm in a rat model of staphylococcal vascular graft infection...
  44. Bauer J, Siala W, Tulkens P, Van Bambeke F. A combined pharmacodynamic quantitative and qualitative model reveals the potent activity of daptomycin and delafloxacin against Staphylococcus aureus biofilms. Antimicrob Agents Chemother. 2013;57:2726-37 pubmed publisher
    ..Delafloxacin and daptomycin were the most potent, reducing viability by more than 50% at clinically achievable concentrations against both ..
  45. Huang D, Jia X, Wen J, Wang G, Yu G, Caiyin Q, et al. Metabolic flux analysis and principal nodes identification for daptomycin production improvement by Streptomyces roseosporus. Appl Biochem Biotechnol. 2011;165:1725-39 pubmed publisher
    In the present work, a comprehensive metabolic network of Streptomyces roseosporus LC-54-20 was proposed for daptomycin production...
  46. Mishra N, Yang S, Chen L, Muller C, Saleh Mghir A, Kuhn S, et al. Emergence of daptomycin resistance in daptomycin-naïve rabbits with methicillin-resistant Staphylococcus aureus prosthetic joint infection is associated with resistance to host defense cationic peptides and mprF polymorphisms. PLoS ONE. 2013;8:e71151 pubmed publisher
    Previous studies of both clinically-derived and in vitro passage-derived daptomycin-resistant (DAP-R) Staphylococcus aureus strains demonstrated the coincident emergence of increased DAP MICs and resistance to host defense cationic ..
  47. Cafiso V, Bertuccio T, Purrello S, Campanile F, Mammina C, Sartor A, et al. dltA overexpression: A strain-independent keystone of daptomycin resistance in methicillin-resistant Staphylococcus aureus. Int J Antimicrob Agents. 2014;43:26-31 pubmed publisher
    The mechanisms leading to reduced susceptibility to daptomycin (DAP) are multifactorial and have not been fully elucidated...
  48. Sakoulas G, Nonejuie P, Nizet V, POGLIANO J, Crum Cianflone N, Haddad F. Treatment of high-level gentamicin-resistant Enterococcus faecalis endocarditis with daptomycin plus ceftaroline. Antimicrob Agents Chemother. 2013;57:4042-5 pubmed publisher
    ..by high-level aminoglycoside-resistant Enterococcus faecalis was successfully treated with ceftaroline and daptomycin. This combination demonstrated excellent synergy in vitro...
  49. Utili R, Cogo A, Cristini F, Prisco V, Sagnelli E, Tascini C, et al. Clinical experience with daptomycin in Italy: results from a registry study of the treatment of Gram-positive infections between 2006 and 2009. J Chemother. 2012;24:113-21 pubmed publisher
    The purpose of this study was to evaluate post-marketing efficacy and safety data for therapy with daptomycin (DAP) in Italy...
  50. Barberán J, Farinas M. [Daptomycin in complicated skin and soft tissue infections]. Enferm Infecc Microbiol Clin. 2012;30 Suppl 1:33-7 pubmed publisher
    ..its spectrum, microbiological activity, pharmacokinetics, and safety, as well as clinical experience in its use, daptomycin seems to be a highly appropriate antibiotic in the treatment of SSTIs, especially those produced by methicillin-..
  51. Kullar R, Davis S, Levine D, Zhao J, Crank C, Segreti J, et al. High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study. Pharmacotherapy. 2011;31:527-36 pubmed publisher
    To evaluate the clinical response and safety of high-dose daptomycin for treatment of complicated gram-positive infections. Multicenter, retrospective, observational, case series analysis...
  52. Steed M, Vidaillac C, Rybak M. Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations. Antimicrob Agents Chemother. 2010;54:5187-92 pubmed publisher
    Reduced susceptibility to daptomycin has been reported in patients with infections due to methicillin-resistant Staphylococcus aureus (MRSA)...
  53. Boyle Vavra S, Jones M, Gourley B, Holmes M, Ruf R, Balsam A, et al. Comparative genome sequencing of an isogenic pair of USA800 clinical methicillin-resistant Staphylococcus aureus isolates obtained before and after daptomycin treatment failure. Antimicrob Agents Chemother. 2011;55:2018-25 pubmed publisher
    We describe here a clinical daptomycin treatment failure in a patient with recurrent methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in whom daptomycin was administered after a failed empirical treatment course with ..